Abstract
Tardive dyskinesia (TD) has been recognised for nearly 50 years. It is associated with antipsychotic drugs and is usually persistent with no satisfactory treatment. It is believed to be under-documented in medical records. Many rating scales have been devised to measure TD. Studies have demonstrated variability between the rating scales on the measures of reliability and validity, the clinical setting used, the raters involved in the ratings and the provision of definitions and instructions. Scales that include too many items to be comprehensive become cumbersome and difficult to use. A compromise is to reduce the number of items and have add-in items for individual patients. A good example of this approach is the Abbreviated Dyskinesia Scale (ADS). Rating scales continue to be the best available methods to evaluate dyskinesia but in view of the shortcomings of validity, reliability and utility for clinical use, more efforts need to be done to improve current rating scales and to develop new ones.
Keywords: Tardive dyskinesia, rating scales, anti-psychotics, movement disorder, schizophrenia
Current Drug Targets
Title: A Critical Review of Rating Scales in the Assessment of Movement Disorders in Schizophrenia
Volume: 7 Issue: 9
Author(s): U. Taksh
Affiliation:
Keywords: Tardive dyskinesia, rating scales, anti-psychotics, movement disorder, schizophrenia
Abstract: Tardive dyskinesia (TD) has been recognised for nearly 50 years. It is associated with antipsychotic drugs and is usually persistent with no satisfactory treatment. It is believed to be under-documented in medical records. Many rating scales have been devised to measure TD. Studies have demonstrated variability between the rating scales on the measures of reliability and validity, the clinical setting used, the raters involved in the ratings and the provision of definitions and instructions. Scales that include too many items to be comprehensive become cumbersome and difficult to use. A compromise is to reduce the number of items and have add-in items for individual patients. A good example of this approach is the Abbreviated Dyskinesia Scale (ADS). Rating scales continue to be the best available methods to evaluate dyskinesia but in view of the shortcomings of validity, reliability and utility for clinical use, more efforts need to be done to improve current rating scales and to develop new ones.
Export Options
About this article
Cite this article as:
Taksh U., A Critical Review of Rating Scales in the Assessment of Movement Disorders in Schizophrenia, Current Drug Targets 2006; 7 (9) . https://dx.doi.org/10.2174/138945006778226589
DOI https://dx.doi.org/10.2174/138945006778226589 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Considerations in the Pharmacotherapy of Bipolar Disorder During and After Pregnancy
Current Drug Safety Diffuse Correlation Spectroscopy (DCS): A Diagnostic Tool for Assessing Tissue Blood Flow in Vascular-Related Diseases and Therapies
Current Medical Imaging The Ever Changing Face of Antibiotic Resistance: Prevailing Problems and Preventive Measures
Current Drug Metabolism Role of Lipid Rafts/Caveolae in the Anticancer Effect of Endocannabinoids
Mini-Reviews in Medicinal Chemistry Noradrenergic System in Down Syndrome and Alzheimer’s Disease A Target for Therapy
Current Alzheimer Research Cysteine Network (CYSTEINET) Dysregulation in Parkinson’s Disease: Role of N-acetylcysteine
Current Drug Metabolism Aceruloplasminemia
Current Drug Targets Objective Biomarkers or Symptom Scores for the Classification of Fibromyalgia Syndrome?
Current Rheumatology Reviews EDITORIAL (Thematic Issue: New Targets of Medical Treatment in Psychiatric Disorders)
Current Neuropharmacology Effects of the Capsular Polysaccharides of Cryptococcus neoformans on Phagocyte Migration and Inflammatory Mediators [General Articles]
Current Medicinal Chemistry Creatine Supplementation: Can it Improve Quality of Life in the Elderly without Associated Resistance Training?
Current Aging Science Gene Expression and Regulation of Higher Plants Under Soil Water Stress
Current Genomics Colchicine: An Ancient Drug with Multiple Benefits
Current Pharmaceutical Design Association of Posture Instability with Dopamine Drop of Nigrostriatal System and Hypometabolism of Cerebral Cortex in Parkinson’s Disease
Current Neurovascular Research Rolipram Rescues Memory Consolidation Deficits Caused by Sleep Deprivation: Implication of the cAMP/PKA and cAMP/Epac Pathways
CNS & Neurological Disorders - Drug Targets Gene Electrotransfer: A Mechanistic Perspective
Current Gene Therapy Delayed Cerebral Ischemia after Subarachnoid Hemorrhage: From Vascular Spasm to Cortical Spreading Depolarizations
Current Neurovascular Research Comparing the Molecular Pharmacology of CGRP and Adrenomedullin
Current Protein & Peptide Science New Inhibitors of Glycogen Phosphorylase as Potential Antidiabetic Agents
Current Medicinal Chemistry Molecular Dynamics Simulation in RNA Interference
Current Medicinal Chemistry